TrivarX Limited (AU:TRI)
ASX:TRI
Want to see AU:TRI full AI Analyst Report?
Top Page
TrivarX Limited
(Sydney:TRI)
Select Model
Select Model
Rating:51Neutral
Price Target:
AU$0.03
▲(50.00% Upside)
Action:ReiteratedDate:05/07/26
The score is held back primarily by weak financial performance (ongoing losses, zero reported revenue, and negative operating/free cash flow), partially cushioned by low leverage and a solid equity base. Technicals are a relative positive with price above major moving averages and positive MACD, but valuation remains pressured by a negative P/E and lack of dividend data.
Positive Factors
Conservative balance sheet
Very low leverage and a growing equity base provide a meaningful solvency cushion for an early-stage healthcare information business. That reduces short-term distress risk, supports continued product development or trials, and gives management time to pursue revenue or partnerships without immediate insolvency pressure.
Negative Factors
Sustained net losses
Repeated net losses erode retained capital and produce negative returns on equity (around -7.5%), limiting internal funding for growth. Persistent unprofitability increases reliance on external finance, raises dilution or interest burdens, and is a structural constraint until revenue or margins improve.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low leverage and a growing equity base provide a meaningful solvency cushion for an early-stage healthcare information business. That reduces short-term distress risk, supports continued product development or trials, and gives management time to pursue revenue or partnerships without immediate insolvency pressure.
Read all positive factors
TrivarX Limited (TRI) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$34.61M
Dividend YieldN/A
Average Volume (3M)1.22M
Price to Earnings (P/E)―
Beta (1Y)2.70
Revenue GrowthN/A
EPS Growth-260.00%
CountryAU
Employees6
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.00
Shares Outstanding1,153,693,500
10 Day Avg. Volume1,871,965
30 Day Avg. Volume1,217,195
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)0.82
Price to Sales (P/S)0.00
P/FCF Ratio-54.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
TrivarX Limited Business Overview & Revenue Model
Company Description
TrivarX Limited, a health technology company, engages in the development of AI-driven, scientifically-based devices for screening and diagnosis of behavioral health conditions in Australia and the United States. The company offers mental well-bein...
TrivarX Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
68
Positive
Cash Flow
22
Negative
| Breakdown | Jun 2024 | Jun 2023 |
|---|---|---|
Income Statement | ||
| Total Revenue | 0.00 | 0.00 |
| Gross Profit | -52.47K | 0.00 |
| EBITDA | -1.89M | -1.13M |
| Net Income | -943.23K | -1.24M |
Balance Sheet | ||
| Total Assets | 13.48M | 10.81M |
| Cash, Cash Equivalents and Short-Term Investments | 1.25M | 848.10K |
| Total Debt | 169.03K | 15.90K |
| Total Liabilities | 831.22K | 1.18M |
| Stockholders Equity | 12.65M | 9.88M |
Cash Flow | ||
| Free Cash Flow | -189.74K | -3.70M |
| Operating Cash Flow | -189.74K | 0.00 |
| Investing Cash Flow | -2.09M | -2.85M |
| Financing Cash Flow | 2.68M | 4.32M |
TrivarX Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | AU$23.38M | 3.95 | 7.57% | ― | 31.36% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$34.61M | -3.08 | -7.84% | ― | ― | -260.00% | |
46 Neutral | AU$14.93M | -2.48 | -578.72% | ― | 43.55% | 26.03% | |
44 Neutral | AU$32.18M | -1.71 | -1122.02% | ― | ― | ― | |
43 Neutral | AU$12.75M | -0.80 | -137.16% | ― | -71.80% | -1044.71% | |
43 Neutral | AU$34.49M | -3.13 | -1009.84% | ― | 13.69% | 7.57% |
* Healthcare Sector Average
AU:TRI
TrivarX Limited
0.03
0.02
130.77%
AU:RHT
Resonance Health Ltd
0.05
0.01
32.43%
AU:PKY
Opyl Ltd.
0.05
0.03
165.00%
AU:AHE
MedAdvisor Limited
0.02
-0.08
-79.80%
AU:ICR
InteliCare Holdings Limited
0.02
0.01
71.43%
AU:PCK
PainChek Ltd
0.17
-0.26
-60.71%
TrivarX Limited Corporate Events
TrivarX Sharpens Focus on Stabl-Im Trials and Appoints New CEO to Drive Commercial Push
Apr 30, 2026
TrivarX advanced development of its Stabl-Im brain imaging technology during the March quarter, refining Phase 1 clinical trial design, progressing manufacturing validation, and initiating early regulatory planning in the U.S. and Europe. The comp...
TrivarX names new CEO to advance Stabl-Im brain cancer imaging platform
Apr 28, 2026
TrivarX has appointed radiopharmaceutical and biotech veteran Dr Danielle Meyrick as chief executive officer from 1 June 2026 to lead clinical and commercial development of its Stabl-Im brain cancer imaging platform. With more than two decades in ...
TrivarX reshapes leadership and governance to drive digital health commercialisation
Mar 4, 2026
TrivarX has terminated the employment of Chief Medical Officer Dr Archie Defillo, who played a key role in developing its MEB-001 and single-channel ECG algorithms, as the company shifts toward a more commercially focused phase. To drive this tran...
TrivarX Flags Sharp Revenue Fall and Wider Loss as Auditor Raises Going-Concern Uncertainty
Feb 24, 2026
TrivarX Limited reported a collapse in revenue from ordinary activities to $2,270 for the half-year ended 31 December 2025, compared with $1.13 million a year earlier, while its net loss attributable to members widened sharply to $1.26 million fro...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.